MetaCap

Vir Biotechnology (VIR) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vir Biotechnology is the larger company by market cap ($1.56 billion vs $1.45 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VIR-15.76%WWB-14.79%
+7%-8%-22%
Nov 13, 20261 yearNov 20, 2026
VIR-15.76%WWB-14.79%
+1%-8%-17%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VIR versus WWB key metrics
MetricVIRWWB
Share price$8.39$24.29
Market cap$1.56B$1.45B
1-day change-5.41%+1.15%
YTD return+39.14%—
1-year return+47.71%—
5-year return-76.69%—
EPS (TTM)$-1.18$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$68.56M—
Revenue growth (YoY)-7.61%—
Net income (latest FY)$-437.99M—
Gross margin99.96%—
Operating margin-699.18%—
Net margin-638.87%—
52-week high$14.38$33.99
52-week low$5.45$18.35
Distance from 52-week high-41.66%-28.55%
Analyst consensusstrong_buy—
Avg. price target upside+178.67%—
Average volume2.45M434.33K
Shares outstanding186.27M59.58M
Employees36733
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Vir Biotechnology

VIR stock →

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

VIR vs WWB FAQ

Which is bigger, Vir Biotechnology or Windward Bio Group?

Vir Biotechnology (VIR) is larger, with a market capitalization of $1.56B compared with $1.45B for Windward Bio Group (WWB).

Are Vir Biotechnology and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons